• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

作者信息

Martino Enrica Antonia, Derudas Daniele, Rossi Elena, Terlizzi Sofia, Reddiconto Giovanni, Stefanoni Paola, Micozzi Jacopo, Mangiacavalli Silvia, Zamagni Elena, Offidani Massimo, Furlan Anna, Buda Gabriele, Lotti Flavia, Liberatore Carmine, Lazzaro Antonio, Della Pepa Roberta, Bertuglia Giuseppe, Barbieri Emiliano, Conticello Concetta, De Magistris Claudio, De Paoli Lorenzo, Bongarzoni Velia, Cafro Anna Maria, Mele Anna, Benvenuti Pietro, Cerchione Claudio, Botta Cirino, Antonioli Elisabetta, Sgherza Nicola, Aquino Sara, Mele Giuseppe, Barilà Gregorio, Palmieri Salvatore, Annibali Ombretta, Bianco Rosario, Febbo Massimiliano Arangio, Casaluci Gloria Margiotta, Rago Angela, Fontana Raffaele, Farina Francesca, Vigna Ernesto, Bruzzese Antonella, Mancuso Katia, Nappi Davide, Morè Sonia, Rivolti Elena, Califano Catello, Amendola Angela, Roccotelli Daniela, Lombardo Alessandra, Citro Annalisa, Uccello Giuseppina, Zambello Renato, Maggi Alessandro, Neri Santo, Monachesi Michele, Gozzetti Alessandro, Montefusco Vittorio, Brunori Marino, Cotzia Emilia, Pietrantuono Giuseppe, Quinto Angela Maria, Amico Valeria, Di Renzo Nicola, Coscia Marta, Galli Monica, De Stefano Valerio, Petrucci Maria Teresa, Neri Antonino, Di Raimondo Francesco, Morabito Fortunato, Musto Pellegrino, Gentile Massimo

机构信息

Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza.

Department of Hematology, Businco Hospital, Cagliari.

出版信息

Haematologica. 2025 Apr 1;110(4):1028-1033. doi: 10.3324/haematol.2024.286658. Epub 2024 Nov 28.

DOI:10.3324/haematol.2024.286658
PMID:39605207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959237/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77b/11959237/d30a2a3cadd4/1101028.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77b/11959237/d30a2a3cadd4/1101028.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a77b/11959237/d30a2a3cadd4/1101028.fig1.jpg

相似文献

1
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.isatuximab、泊马度胺和地塞米松作为多发性骨髓瘤患者的挽救治疗：意大利多中心非对照临床试验外270例患者的回顾性临床经验
Haematologica. 2025 Apr 1;110(4):1028-1033. doi: 10.3324/haematol.2024.286658. Epub 2024 Nov 28.
2
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.ICARIA-MM 研究中伴有高危细胞遗传学的复发/难治性多发性骨髓瘤患者的亚组分析。
Br J Haematol. 2021 Jul;194(1):120-131. doi: 10.1111/bjh.17499. Epub 2021 May 25.
3
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
4
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.依既往治疗线数和难治状态分层的复发/难治性多发性骨髓瘤患者中伊沙佐米联合泊马度胺和地塞米松治疗：ICARIA-MM 亚组分析。
Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.
5
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、3 期研究的随访分析。
Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10.
6
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.EMA 审查伊沙妥昔单抗联合泊马度胺和地塞米松治疗复发和难治性多发性骨髓瘤的成人患者。
Oncologist. 2021 Nov;26(11):983-987. doi: 10.1002/onco.13892. Epub 2021 Jul 19.
7
Isatuximab: A Review of Its Use in Multiple Myeloma.依沙妥昔单抗：在多发性骨髓瘤中的应用评价。
Target Oncol. 2021 Sep;16(5):675-686. doi: 10.1007/s11523-021-00827-0. Epub 2021 Aug 5.
8
An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.依沙佐米、泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤成年患者的评估。
Expert Rev Hematol. 2021 May;14(5):419-427. doi: 10.1080/17474086.2021.1924052. Epub 2021 May 16.
9
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.依洛珠单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤：在对照临床试验之外，对 321 例多中心回顾性真实世界经验的扩展随访。
Hematol Oncol. 2024 Jul;42(4):e3290. doi: 10.1002/hon.3290.
10
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.埃罗妥珠单抗、来那度胺和地塞米松作为多发性骨髓瘤患者的挽救治疗：意大利多中心非对照临床试验之外300例患者的回顾性临床经验
Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.

引用本文的文献

1
Comparison of isatuximab-pomalidomide-dexamethasone elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data.复发/难治性多发性骨髓瘤患者中isatuximab-泊马度胺-地塞米松与elotuzumab-泊马度胺-地塞米松的比较：一项使用真实世界数据的目标试验模拟。
Haematologica. 2025 Mar 6;110(8):1875-1881. doi: 10.3324/haematol.2025.287325.
2
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.达雷妥尤单抗、埃罗妥珠单抗和卡非佐米三联方案治疗复发/难治性多发性骨髓瘤时+1q改变的预后意义：635例患者的多中心真实世界分析
Eur J Haematol. 2025 Jul;115(1):16-28. doi: 10.1111/ejh.14413. Epub 2025 Mar 19.
3

本文引用的文献

1
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.在真实世界中，伊沙妥昔单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤患者：回顾性 IMAGE 研究。
Eur J Haematol. 2024 Sep;113(3):290-297. doi: 10.1111/ejh.14225. Epub 2024 May 7.
2
Isatuximab-pomalidomide-dexamethasone pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.依沙佐米-泊马度胺-地塞米松与泊马度胺-地塞米松在复发和难治性多发性骨髓瘤患者中的疗效：最终总生存分析。
Haematologica. 2024 Jul 1;109(7):2239-2249. doi: 10.3324/haematol.2023.284325.
3
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.isatuximab、泊马度胺和地塞米松（IsaPd）治疗达雷妥尤单抗难治性多发性骨髓瘤患者的疗效及预后指标：一项多中心真实世界研究
Hematol Oncol. 2025 Mar;43(2):e70042. doi: 10.1002/hon.70042.
Isatuximab in multiple myeloma.
isatuximab治疗多发性骨髓瘤
Expert Opin Biol Ther. 2023 Apr;23(4):315-318. doi: 10.1080/14712598.2023.2193289. Epub 2023 Mar 24.
4
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.isatuximab治疗的复发/难治性多发性骨髓瘤患者按1q21+状态划分的主要结局：来自ICARIA-MM和IKEMA的亚组分析
Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660.
5
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.isatuximab联合泊马度胺和地塞米松治疗复发骨髓瘤的疗效：一项全英国真实世界数据集的结果
Hemasphere. 2022 May 26;6(6):e738. doi: 10.1097/HS9.0000000000000738. eCollection 2022 Jun.
6
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.卡非佐米联合来那度胺和地塞米松（KRd）作为多发性骨髓瘤患者的挽救治疗：意大利多中心非对照临床试验外600例患者的回顾性临床经验
Hematol Oncol. 2022 Dec;40(5):1009-1019. doi: 10.1002/hon.3035. Epub 2022 Jun 6.
7
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.isatuximab、卡非佐米和地塞米松用于复发多发性骨髓瘤（IKEMA）：一项多中心、开放标签、随机3期试验
Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4.
8
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.ICARIA-MM 研究中伴有高危细胞遗传学的复发/难治性多发性骨髓瘤患者的亚组分析。
Br J Haematol. 2021 Jul;194(1):120-131. doi: 10.1111/bjh.17499. Epub 2021 May 25.
9
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.isatuximab联合泊马度胺和地塞米松治疗复发/难治性老年多发性骨髓瘤患者：ICARIA-MM亚组分析
Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.
10
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.埃罗妥珠单抗、来那度胺和地塞米松作为多发性骨髓瘤患者的挽救治疗：意大利多中心非对照临床试验之外300例患者的回顾性临床经验
Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.